Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Bezafibrate26 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A07125 | 32613381 | Cell Biol Toxicol | Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. | 2020 | Details |
| A10110 | 31480575 | Biomolecules | Raw Bowl Tea (Tuocha) Polyphenol Prevention of Nonalcoholic Fatty Liver Disease by Regulating Intestinal Function in Mice. | 2019 | Details |
| A10392 | 31357780 | Zhonghua Gan Zang Bing Za Zhi | [A new attempt with lipoprotein lipase agonists in the treatment of nonalcoholic steatohepatitis]. | 2019 | Details |
| A10804 | 31182918 | Int J Biol Sci | A Comprehensive Study of High Cholesterol Diet-Induced Larval Zebrafish Model: A Short-Time In Vivo Screening Method for Non-Alcoholic Fatty Liver Disease Drugs. | 2019 | Details |
| A12854 | 30256948 | Hum Mol Genet | Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia. | 2019 | Details |
| A16638 | 28271032 | Mol Metab | Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice. | 2017 | Details |
| A20763 | 25748419 | Life Sci | Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice. | 2015 | Details |
| A21472 | 25296088 | Arq Gastroenterol | Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention? | 2015 | Details |
| A21897 | 24975050 | Basic Clin Pharmacol Toxicol | Effects of antihypertensive and triglyceride-lowering agents on hepatic copper concentrations in rats with fatty liver disease. | 2014 | Details |
| A22471 | 24534255 | Toxicol Appl Pharmacol | PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. | 2014 | Details |
| A23726 | 23531105 | Lipids Health Dis | Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective. | 2013 | Details |
| A23776 | 23489555 | Basic Clin Pharmacol Toxicol | Effects of antihypertensive and triglyceride lowering agents on splenocyte apoptosis in rats with fatty liver. | 2013 | Details |
| A25342 | 21946918 | Mol Med Rep | Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet. | 2011 | Details |
| A25682 | 21549692 | Eur J Pharmacol | Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome. | 2011 | Details |
| A26654 | 20040336 | Int J Clin Pharmacol Ther | Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. | 2010 | Details |
| A28279 | 15824194 | Hypertension | Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. | 2005 | Details |
| A28458 | 14598660 | Ryumachi | [Systemic lupus erythematosus with steroid induced non-alcoholic steatohepatitis: a case report]. | 2003 | Details |
| A28473 | 12883726 | Oncol Rep | Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate. | 2004 | Details |
| A36291 | 18513333 | Hepatol Res | Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line. | 2008 | Details |
| A37053 | 16574099 | Eur J Pharmacol | Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. | 2006 | Details |
| A38510 | 11078796 | Int J Oncol | Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. | 2000 | Details |
| A46707 | 16322887 | Breast Cancer Res Treat | Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist. | 2006 | Details |
| A48414 | 12058881 | Intern Med | Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. | 2002 | Details |
| A50017 | 35563117 | Int J Mol Sci | Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate. | 2022 | Details |
| A52850 | 20699090 | Clin Chim Acta | Triglycerides and gallstone formation. | 2010 | Details |
| A53118 | 12401884 | J Lipid Res | AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. | 2002 | Details |